Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coronary syndromes: a survey of cardiologists' attitudes and practice.
作者信息
Slater Thomas A, Drozd Michael, Palin Victoria, Bowles Charlotte, Waduud Mohammed A, Khatib Rani, Ajjan Ramzi A, Wheatcroft Stephen B
机构信息
Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Clarendon Way, Leeds LS2 9JT, UK.
Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Great George St, Leeds LS1 3EX, UK.
出版信息
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):194-196. doi: 10.1093/ehjcvp/pvz058.
Abstract
摘要
相似文献
1
Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coronary syndromes: a survey of cardiologists' attitudes and practice.为急性冠状动脉综合征患者开具降糖药物以降低心血管风险：心脏病专家的态度与实践调查
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):194-196. doi: 10.1093/ehjcvp/pvz058.
2
Are We Ready to Bell The Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes.我们准备好挑战难题了吗？呼吁心脏病专家采用已证实能改善心血管结局的降糖疗法。
Circulation. 2018 Jul 3;138(1):4-6. doi: 10.1161/CIRCULATIONAHA.117.022680.
3
The shifting paradigm in the treatment of type 2 diabetes mellitus-A cardiologist's perspective.2型糖尿病治疗模式的转变——心脏病专家的观点
Clin Cardiol. 2017 Nov;40(11):970-973. doi: 10.1002/clc.22781. Epub 2017 Aug 25.
4
Knowledge and prescribing behaviour of Flemish general practitioners regarding novel glucose-lowering medications: Online cross-sectional survey.关于新型降糖药物，佛兰德全科医生的知识和处方行为：在线横断面调查。
Prim Care Diabetes. 2024 Aug;18(4):441-447. doi: 10.1016/j.pcd.2024.06.002. Epub 2024 Jun 11.
5
Trends in utilization patterns of newer glucose-lowering drugs in US adults with type 2 diabetes and a history of coronary heart disease or heart failure: 2005-2019.2005-2019 年美国有冠心病或心力衰竭史的 2 型糖尿病成人中新的降糖药物利用模式趋势。
Prim Care Diabetes. 2024 Oct;18(5):561-563. doi: 10.1016/j.pcd.2024.07.003. Epub 2024 Aug 2.
6
Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease.心血管益处备受关注：将2型糖尿病治疗模式转向对明显心血管疾病患者进行早期联合治疗。
Cardiovasc Diabetol. 2018 Aug 22;17(1):117. doi: 10.1186/s12933-018-0760-6.
7
Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfil guideline recommended targets? A report from the EUROASPIRE III cross-sectional study.患有明确冠状动脉疾病和糖尿病的患者的药物治疗是否符合指南推荐的目标？来自 EUROASPIRE III 横断面研究的报告。
Eur J Prev Cardiol. 2015 Jun;22(6):753-61. doi: 10.1177/2047487314529353. Epub 2014 Apr 1.
8
Regular mailing of personalized feedback reports improves glycemic control in diabetes: A randomized controlled trial.
J Diabetes. 2017 May;9(5):536-538. doi: 10.1111/1753-0407.12527. Epub 2017 Mar 5.
9
SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives.SGLT2抑制剂或GLP-1受体激动剂作为2型糖尿病的二线治疗：患者选择及前景
Vasc Health Risk Manag. 2016 Jun 4;12:239-49. doi: 10.2147/VHRM.S83088. eCollection 2016.
10
Emerging glucose-lowering therapies: a guide for cardiologists.新兴的降糖治疗药物：心内科医生实用指南。
Heart. 2020 Jan;106(1):18-23. doi: 10.1136/heartjnl-2019-315758. Epub 2019 Sep 24.
引用本文的文献
1
Health Care Provider Prescribing Habits and Barriers to Use of New Type 2 Diabetes Medications: A Single-System Survey Study.医疗服务提供者的处方习惯及新型2型糖尿病药物使用障碍：单系统调查研究
Clin Diabetes. 2023 Fall;41(4):490-501. doi: 10.2337/cd22-0100. Epub 2023 Apr 14.
2
Assessment of Knowledge and Perception of Sodium-Glucose Co-transporter 2 (SGLT-2) Inhibitors Prescription among Physicians in Saudi Arabia.评估沙特阿拉伯医生对钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂处方的知识和认知。
Curr Diabetes Rev. 2024;20(4):e060723218471. doi: 10.2174/1573399820666230706125244.
3
The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study.钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂在 2 型糖尿病患者中的处方模式：一项两中心回顾性横断面研究。
Front Public Health. 2022 Oct 28;10:1031306. doi: 10.3389/fpubh.2022.1031306. eCollection 2022.
4
Strategic Recommendations to Bridge the Gaps in Awareness, Diagnosis and Prevention of Heart Failure in the Middle East Region and Africa.弥合中东地区和非洲心力衰竭认知、诊断与预防差距的战略建议。
J Saudi Heart Assoc. 2022 Apr 15;34(1):53-65. doi: 10.37616/2212-5043.1294. eCollection 2022.
5
National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.2015 年至 2020 年，心脏病专家和其他专业医生使用钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂的全国趋势。
J Am Heart Assoc. 2022 May 3;11(9):e023811. doi: 10.1161/JAHA.121.023811. Epub 2022 Apr 27.
6
Quality of Diabetes Care in the USA.美国的糖尿病护理质量。
Curr Cardiol Rep. 2021 Jun 3;23(7):73. doi: 10.1007/s11886-021-01503-5.
本文引用的文献
1
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.2019年欧洲心脏病学会（ESC）与欧洲糖尿病研究协会（EASD）合作制定的糖尿病、糖尿病前期和心血管疾病指南。
Eur Heart J. 2020 Jan 7;41(2):255-323. doi: 10.1093/eurheartj/ehz486.
2
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.2018年美国心脏病学会专家共识决策路径：2型糖尿病合并动脉粥样硬化性心血管疾病患者降低心血管风险的新型疗法：美国心脏病学会专家共识决策路径特别工作组报告
J Am Coll Cardiol. 2018 Dec 18;72(24):3200-3223. doi: 10.1016/j.jacc.2018.09.020. Epub 2018 Nov 26.
3
Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable.应对2型糖尿病中的心血管风险：欧洲心脏病学会心血管圆桌会议报告
Eur Heart J. 2019 Sep 7;40(34):2907-2919. doi: 10.1093/eurheartj/ehy677.
4
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与 2 型糖尿病的心血管和肾脏事件。
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
5
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.利拉鲁肽与2型糖尿病患者的心血管结局
N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
6
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.恩格列净：在 2 型糖尿病中的心血管结局和死亡率。
N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
7
International differences in acute coronary syndrome patients' baseline characteristics, clinical management and outcomes in Western Europe: the EURHOBOP study.西欧急性冠状动脉综合征患者的基线特征、临床管理及预后的国际差异：EURHOBOP研究
Heart. 2014 Aug;100(15):1201-7. doi: 10.1136/heartjnl-2013-305196. Epub 2014 May 1.
8
Effects of intensive glucose lowering in type 2 diabetes.强化降糖对2型糖尿病的影响。
N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6.
9
Why don't physicians follow clinical practice guidelines? A framework for improvement.医生为何不遵循临床实践指南？一个改进框架。
JAMA. 1999 Oct 20;282(15):1458-65. doi: 10.1001/jama.282.15.1458.
Zotero 插件